PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Diroximel→

Diroximel PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1577222-14-0
Molecular formula
C11H13NO6
Molecular weight
255.22 g/mol
Drug class
Fumarate prodrugdisease-modifying therapy for multiple sclerosis
Mechanism of action
Rapidly hydrolysed to monomethyl fumarate (MMF), the same active metabolite formed from dimethyl fumarate. The mechanism of MMF in multiple sclerosis is not fully understood; Nrf2 pathway activation and modulation of inflammatory and oxidative-stress responses are proposed.
Indications / reported uses
  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211855s002lbl.pdf · https://www.ncbi.nlm.nih.gov/sites/books/NBK548484/

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Diroximel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diroximel Permitted Daily Exposure (PDE) report (the Diroximel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diroximel Occupational Exposure Limit (OEL) report (the Diroximel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.